中证报中证网讯（王珞）8月26日晚间，中关村（000931）（000931）发布2025年半年度报告。报告期 内，公司实现营业收入12.39亿元，同比下降2.71%；实现净利润3881万元，同比增长6.65%；扣非净利 润3685万元，同比增长36.34%。 此外，公司健康品业务持续推进"华素愈创""华素清清"等产品的终端推广和营销升级工作。报告期内， 先后参加北京国际口腔展、华南国际口腔展、东北国际口腔展、江西省口腔展会四大口腔展会。通过与 连锁药店战略合作和区域代理商合作等手段，推进产品市场覆盖范围，扩大业务规模，提升品牌知名 度。报告期内，中关村已与多家口腔诊所达成合作意向，后续公司将继续推进相关工作的进一步开展。 北京华素OTC渠道销售方面，在产品策划端，公司通过整合多元宣传手段，精准锚定目标受众，构建品 牌传播矩阵，提升品牌知名度。在销售端，紧密携手头部连锁企业，高效推进铺货进程。同时，高频次 开展市场推广活动，全方位赋能终端动销。报告期内，"华素片""盐酸苯环壬酯片（商品名：飞赛 乐）"等主要产品均较好地完成半年度销售任务；其中，"华素片"与"风度片"在乌镇健康大会中斩获"最 受药店欢迎的明星单品 ...

本报讯 （记者向炎涛）8月26日晚，北京中关村科技发展（控股）股份有限公司（以下简称"中关村"） 发布2025年半年度报告。上半年，公司实现营业收入12.39亿元，较上年同期基本持平；实现归属于上 市公司股东的净利润3880.89万元，同比增长6.65%；实现归属于上市公司股东的扣除非经常性损益的净 利润3685.49万元，同比增长36.34%。 报告期内，公司继续聚焦主业，推动精细化管理迈向更高阶段。同时，公司坚持内外结合，充分利用外 部资源，完善、丰富产品线，保持投入，夯实未来发展基础。 生物医药及健康品业务方面，公司药品生产和研发工作取得积极进展。报告期内，公司旗下北京华素收 到北京市药品监督管理局下发的《药品生产许可证》，生产范围增加原料药联苯苄唑，有利于公司优化 生产结构，丰富公司产品布局，满足市场需求。 药品销售工作方面，北京华素主要产品富马酸比索洛尔片（商品名：博苏）销量与上年同期基本持平， 核心产品盐酸贝尼地平片（注册商标：元治®）较上年同期继续保持增长；同时，战略产品"盐酸羟考 酮注射液"营业收入较上年同期增长逾90%。报告期内，"盐酸纳洛酮注射液"成功中选第十批国家组织 药品集中采购。 作 ...

8月26日晚间，中关村（000931）（000931.SZ）披露2025年半年度报告。2025年上半年公司实现营业收 入12.39亿元，同比基本持平；利润维持稳健增长，归母净利润及扣非净利润分别实现3880.89万元及 3685.49万元，同比增长6.65%及36.34%。 以核心产品盐酸贝尼地平片（注册商标：元治 ）为例。据了解，该产品用于原发性高血压治疗，在临 床上显现出良好的脏器保护作用，具备较高的安全性，因而受到市场广泛认可。药融云数据显示，早在 2022年"元治"已占据了该品种55%的市场份额。近几年来，在此基础上公司多措并举推动市场开拓，并 于2023年起未雨绸缪加快非集采市场布局，建立起"元治"扎实的市场基础，高份额基础上仍实现了近几 年20%以上的增速，2025年上半年延续正增长。此外，在集采压力下，公司另一主要产品富马酸比索洛 尔片（商品名：博苏）报告期内销量同比基本持平，也保障了公司的业绩基石。 上半年，公司医药主业地位持续巩固，生物医药板块收入占比稳步提升至80%以上。公司在以成熟产品 销售筑牢业绩根基的同时，坚持研发创新，持续丰富产品矩阵。麻精类药品出色的销售增长、多产品管 线扎实的研 ...

Core Viewpoint - The company has demonstrated strong financial performance in Q1 2025, with a net profit of 15.76 million yuan, representing a year-on-year growth of 35.47%, and a non-recurring net profit of 14.86 million yuan, up 124.92% year-on-year, attracting significant attention from institutional investors [1][2]. Financial Performance - In Q1 2025, the company achieved a net profit of 15.76 million yuan, a 35.47% increase compared to the previous year, and a non-recurring net profit of 14.86 million yuan, which is a 124.92% increase year-on-year [1]. - The net profit growth rates for 2023, 2024, and Q1 2025 were 222.72%, 10.33%, and 35.47%, respectively, indicating a consistent upward trend in profitability [2]. Sales Strategy - The company has implemented a "three-full strategy" focusing on comprehensive product promotion, channel expansion, and terminal coverage, which has driven sales growth, particularly in the cardiovascular sector [2]. - The core products, including the antihypertensive drug "Yuan Zhi" (Benidipine Hydrochloride Tablets) and "Bo Su" (Bisoprolol Fumarate Tablets), have significantly contributed to sales, with "Yuan Zhi" sales expected to grow nearly 29% in 2024 [2][3]. Market Position - "Yuan Zhi" has captured a market share of 55.57% as the first generic product in China, indicating strong competitive positioning and market penetration [3]. - The company is proactively preparing for potential future participation in centralized procurement markets while focusing on non-procurement market strategies to mitigate impacts [3]. Product Development - The company is expanding its product matrix in the analgesic sector, with a focus on the opioid "Hydromorphone" series, which has seen a sales increase of 742.22% in 2024, positioning it as a significant product alongside "Yuan Zhi" [5][6]. - The company is also advancing its pipeline in the psychiatric medication sector with the development of methylphenidate formulations, targeting the ADHD market, which is projected to grow significantly [7][8]. Future Outlook - The company anticipates continued revenue and profit growth in 2025, driven by the steady performance of core products and the accelerated release of analgesic medications [9]. - The strategic focus on innovation aims to establish the company as a leading player in the pharmaceutical industry, encompassing chronic disease management and specialty medications [9].